Senores Pharmaceuticals Limited (SENORES) reports a robust Q1 FY27 with revenue up 36% and EBITDA & PAT surging by 87% and 56% respectively.
Senores Pharmaceuticals Limited (SENORES) reports strong Q4 & FY26 results with revenue up 66% and PAT surge of 219%.